Chemotherapy-free treatment targeting fusions and driver mutations in <i>KRAS</i> wild-type pancreatic ductal adenocarcinoma, a case seriesMaahum Mehdi, Mandana Kamgar, Susan Tsai et al.|Therapeutic Advances in Medical Oncology|2024Cited by 5
Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal AdenocarcinomaMandana Kamgar, Thomas McFall, G. Aaron Hobbs et al.|Cancer Research|2025Cited by 3